Merck– tag –
-
Biotech M&A Heats Up: Merck KGaA Acquires Bio-Techne for $11.3B to Bolster Life Science Tools for Cell and Gene Therapy
Fintent United States Overview Fintent's September 8, 2026, report forecasts intensified M&A activity in healthcare and life sciences, highlighting Merck KGaA's $11.3 billion acquisition of Bio-Techne. This strategic move aims to str... -
Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Life Science Tools for Cell and Gene Therapy Workflows
BioBucks United States Overview Merck KGaA has agreed to acquire life science tools provider Bio-Techne for $11.3 billion, a strategic move to significantly enhance its life science division. This acquisition deepens Merck KGaA's exposur... -
Biopharma M&A Surges in H1 2026, Led by Sun Pharma’s $11.75B Organon Acquisition and Merck KGaA’s $11.3B Bio-Techne Deal
Herbert Smith Freehills Kramer Global Overview The first half of 2026 witnessed a significant resurgence in pharmaceutical M&A activity, with several major acquisitions driving market consolidation. Notable transactions include Sun P... -
MSD-Moderna Personalized mRNA Neoantigen Combination Adjuvant Therapy Reports Positive Phase III Results in Melanoma
European Pharmaceutical Review USA Overview MSD (Merck) and Moderna's personalized mRNA neoantigen combination adjuvant therapy has announced positive results from its Phase III clinical trial in high-risk melanoma patients. The data sug... -
Merck Ups 2026 Guidance on Strong Q2, KEYTRUDA Bladder Cancer Expansion, and ENFLONSIA RSV Indication Broadening Bolstering Investment Story
Simply Wall St USA Overview Merck achieved robust Q2 2026 performance and subsequently upgraded its full-year guidance, driven by key regulatory advancements. The company's investment narrative is significantly strengthened by the new bl... -
Merck’s sBLA for ENFLONSIA™ Accepted by FDA for Expanded RSV Prophylaxis in High-Risk Infants Under Two for Second Season
Merck.com (News releases) USA Overview Merck announced that the U.S. FDA has accepted its supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its Respiratory Syncytial Virus (RSV) lower respirato... -
Merck Achieves Robust Q2 2026 Performance, Upgrades Full-Year Guidance, and Empatran Secures FDA Breakthrough Therapy Designation for Lupus
Merck USA Overview Merck reported strong second-quarter 2026 financial results and consequently upgraded its full-year guidance, bolstered by the U.S. FDA's Breakthrough Therapy Designation for Empatran in July. Empatran, developed for l... -
Merck Expands Singapore BioReliance Lab with Asia Pacific’s First Cell Line Characterization and GMP NGS Capabilities
BioPharma APAC Singapore Overview Merck is expanding its Singapore BioReliance lab to strengthen analytical and biosafety testing services in the Asia Pacific region. The expanded facility will offer the first BioReliance Cell Line Chara... -
Merck/Kelun-Biotech ADC Candidate Sac-TMT Demonstrates Superior Progression-Free Survival Over Chemotherapy in China Phase 3 Lung Cancer Study
Endpoints News USA Overview Merck's partner Kelun-Biotech announced positive Phase 3 study results in China for sac-TMT, an experimental antibody-drug conjugate (ADC). In non-squamous non-small cell lung cancer, sac-TMT combined with imm... -
Biopharma M&A Accelerates in H1 2026: Eli Lilly Leads with Over $25 Billion Spend as Big Pharma Bolsters Pipelines
BioPharma Dive USA Overview Biopharmaceutical M&A activity significantly accelerated in the first half of 2026, with over 50 deals transacted. Eli Lilly was notably active, spending over $25 billion and solidifying its position as a ...
12